Researchers at UC Berkeley and UC San Francisco have developed a CRISPR-based approach to selectively destroy cancer cells with a specific mutation in the p53 tumor suppressor gene. This method, called RNA-triggered chromatin shredding, can target "undruggable" cancers and potentially open up new targets for cancer therapy.